During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar filgrastim could result in substantial savings.
The role of biosimilars in Canadian healthcare systems has been increasingly in the spotlight in recent months, with an advisory council recommending biosimilar use as a way to achieve universal public coverage for pharmaceuticals, but with some patient groups—and reference product sponsors—opposing provincial switching programs that seek to transition patients to biosimilar products.
It is in this milieu that, during this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar filgrastim could result in substantial savings. The study, conducted by researchers from the University of Saskatchewan and the University of Alberta, focused on the Health Canada—approved biosimilar Grastofil, made by Apotex, which was introduced in Canada in 2016.
In a retrospective analysis of IQVIA data on Canadian drug purchases from 2016 to 2018, the investigators stratified samples by region, market size, and center type, and calculated cost savings on a quarterly basis by province.
They found that, during the period studied, the biosimilar accounted for 27% of filgrastim purchases, and a total of $62,061,576 (USD $47,127,078) in spending, while the brand-name filgrastim, Neupogen, accounted for $204,152,590 (USD $155,025,310). Biosimilar use therefore generated $13,443,873 (USD $10,208,739) in savings, but could have generated $36,348,476 (USD $27,601,578) had the biosimilar been used in 100% of cases.
The researchers note that the overall percentage of biosimilar filgrastim used in each Canadian province varied widely; market share for the biosimilar was as low as 0.08% in Nova Scotia and as high as 81.62% in Saskatchewan. In the largest Canadian province, Ontario, the biosimilar represented 44.7% of filgrastim use during the study period.
According to the authors, using biosimilars is an opportunity to save money in an overextended healthcare system, and while using Grastofil did generate some savings, increased biosimilar use will produce greater financial benefits.
Reference
Bhimji H, Eurich D, Mansell K, Mansell H. Potential and realized cost savings with the use of the biosimilar Grastofil vs Neupogen. Presented at: The 61th Annual Meeting and Exposition of the American Society of Hematology; December 7-10, 2019; Orlando, FL. Abstract 2126.
CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets
February 6th 2025The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.